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The MDM2–p53–pyruvate carboxylase signalling
axis couples mitochondrial metabolism to
glucose-stimulated insulin secretion in pancreatic
b-cells
Xiaomu Li1,2,3,*, Kenneth K.Y. Cheng1,2,*, Zhuohao Liu1,2, Jin-Kui Yang4, Baile Wang1,2, Xue Jiang1,2, Yawen
Zhou1,2, Philip Hallenborg5, Ruby L.C. Hoo1,2, Karen S.L. Lam1,2, Yasuhiro Ikeda6, Xin Gao3 & Aimin Xu1,2,7
Mitochondrial metabolism is pivotal for glucose-stimulated insulin secretion (GSIS) in
pancreatic b-cells. However, little is known about the molecular machinery that controls the
homeostasis of intermediary metabolites in mitochondria. Here we show that the activation
of p53 in b-cells, by genetic deletion or pharmacological inhibition of its negative regulator
MDM2, impairs GSIS, leading to glucose intolerance in mice. Mechanistically, p53 activation
represses the expression of the mitochondrial enzyme pyruvate carboxylase (PC), resulting
in diminished production of the TCA cycle intermediates oxaloacetate and NADPH, and
impaired oxygen consumption. The defective GSIS and mitochondrial metabolism in
MDM2-null islets can be rescued by restoring PC expression. Under diabetogenic conditions,
MDM2 and p53 are upregulated, whereas PC is reduced in mouse b-cells. Pharmacological
inhibition of p53 alleviates defective GSIS in diabetic islets by restoring PC expression.
Thus, the MDM2–p53–PC signalling axis links mitochondrial metabolism to insulin secretion
and glucose homeostasis, and could represent a therapeutic target in diabetes.
DOI: 10.1038/ncomms11740 OPEN
1 State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pok Fu Lam, Hong Kong. 2 Department of Medicine, The University of
Hong Kong, Pok Fu Lam, Hong Kong. 3 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai 20032, China.
4 Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. 5 Department of
Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark. 6Department of Molecular Medicine, Mayo Clinic, Rochester,
Minnesota 55905, USA. 7Department of Pharmacology & Pharmacy, The University of Hong Kong, Pok Fu Lam, Hong Kong. * These authors contributed
equally to this work. Correspondence and requests for materials should be addressed to K.K.Y.C. (email: dorncky@hku.hk) or to A.X. (email: amxu@hku.hk).
NATURE COMMUNICATIONS | 7:11740 |DOI: 10.1038/ncomms11740 |www.nature.com/naturecommunications 1
G
lucose-stimulated insulin secretion (GSIS) is tightly
controlled by a complex metabolic process involving
mitochondrial oxidative metabolism in pancreatic
b-cells1,2. Dysregulation of this process contributes to the
development of diabetes3. Mitochondria act as fuel sensors and
generators that couple glucose metabolism to insulin secretion
by producing numerous coupling factors through the
tricarboxylic acid (TCA) cycle. In mitochondria, pyruvate
derived from glycolysis is metabolized to generate NADH and
FADH2, which are subsequently oxidized via the respiration
chain to produce ATP. An increase of ATP/ADP ratio
induces closure of the ATP-sensitive potassium (KATP)
channel, leading to membrane depolarization and calcium
inﬂux, which in turn result in ﬁrst-phase insulin secretion1. On
the other hand, the byproducts such as NADPH, a-ketoglutarate
and GTP generated during mitochondrial pyruvate cycling
in the TCA cycle act as amplifying factors for second-phase
insulin secretion4. These metabolic pathways are coordinated
by various mitochondrial enzymes, such as malic enzymes,
pyruvate dehydrogenase kinase and pyruvate carboxylase (PC)4,
yet their molecular regulation and precise roles in the
pathogenesis of b-cell dysfunction in diabetes remain largely
unknown.
The transcription factor p53 is a well-established tumour
suppressor that can be activated by a wide range of stresses, for
example, DNA damage and oxidative stress5. Emerging evidence
has suggested a role for p53 in obesity- and ageing-related
cardiometabolic disorders, such as insulin resistance, endothelial
dysfunction, liver and heart diseases5–10. In obesity, augmented
p53 expression in adipose tissues causes metabolic inﬂammation
by triggering cellular senescence. p53 activity is upregulated in
pancreatic b-cells in diabetic patients and rodents, and is induced
by diabetogenic agents such as streptozotocin and palmitic acid in
primary mouse islets11–13. Systemic overexpression of the short
isoform of p53 (which stabilizes p53 and mediates its activation)
reduces b-cell proliferation, leading to glucose intolerance and
hypoinsulinaemia in mice14. On the contrary, global knockout
of p53 alleviates streptozotocin-induced diabetes, at least in part,
by preserving b-cell mass12. Despite these promising ﬁndings,
interpretation of the data from the global p53 transgenic and
knockout mice is hindered by the fact that the p53 actions in
other metabolic organs may also contribute to the altered
metabolic phenotypes. Therefore, the roles of p53 in b-cell
function, especially GSIS, are yet to be clearly deﬁned.
The activity of p53 is tightly controlled by its upstream negative
regulator mouse double minute 2 (MDM2). This ubiquitin E3
ligase promotes proteasomal degradation and blocks the tran-
scriptional activity of p53 through the direct interaction and
ubiquitination15. As MDM2 itself is a downstream target of p53,
induction of its expression by p53 results in an autoregulatory
negative feedback loop that returns MDM2 and p53 to a basal
level. Perturbations in their balance not only contribute to cancer
development but also to metabolic disorders5. For instance, genetic
abrogation of MDM2 in hepatocytes causes unrestrained p53
activation, leading to liver ﬁbrosis in mice7. In addition, disruption
of this feedback loop perturbs metabolic adaption to starvation,
resulting in fatty liver disease6.
Here we employ b-cell-speciﬁc genetic knockout and
pharmacological blockade approaches to investigate the role of
the MDM2–p53 axis in b-cell functions. Our results show that
the MDM2–p53 axis is essential for mitochondrial oxidative
metabolism and subsequent GSIS in b-cells by regulating
the mitochondrial enzyme PC. Furthermore, we explore
the feasibility to reverse impaired GSIS in type 2 diabetic
mice by pharmacological intervention of the MDM2–p53
signalling axis.
Results
Inhibition of MDM2 impairs GSIS and glucose tolerance. To
determine whether disruption of the MDM2–p53 axis has any
impact on b-cell functions, we generated b-cell-speciﬁc MDM2
knockout (b-MDM2KO) mice by crossing MDM2ﬂoxed/ﬂoxed mice
with transgenic mice expressing Cre recombinase under
the control of rat insulin II promoter (RIP-Cre mice)16.
Immunoﬂuorescence staining and immunoblotting revealed a
marked decrease of MDM2 protein to a virtually undetectable
level in pancreatic islets, but not in exocrine cells of b-MDM2KO
mice (Fig. 1a,b). On the contrary, protein level of p53 was
signiﬁcantly upregulated by B2.1-fold in islets of b-MDM2KO
mice when compared with those in wild-type (WT) littermates
(MDM2ﬂoxed mice without Cre) (Fig. 1b). In addition, MDM2
null islets displayed a moderate but statistically signiﬁcant
increase in mRNA level of p21 (the canonical p53 target),
compared with WT controls (Supplementary Fig. 1a). On the
other hand, immunoblotting revealed that there was no
obvious difference in expression of hypothalamic MDM2 and
p53 between the two groups of mice (Supplementary Fig. 1b).
Genetic deletion of MDM2 had no obvious effect on food intake,
body weight, insulin and glucose levels under fasting conditions
(Supplementary Table 1). However, male b-MDM2KO mice
exhibited a marked impairment in glucose tolerance on glucose
challenge when compared with their WT littermates or RIP-Cre
controls (Fig. 1c). The impaired glucose tolerance in male
b-MDM2KO mice was associated with defective GSIS and
independent of insulin sensitivity, as determined by insulin
tolerance test (ITT; Fig. 1d,e). Likewise, glucose intolerance and
defective GSIS were also observed in female b-MDM2KO mice
(Supplementary Fig. 2). On the other hand, insulin secretion
induced by L-arginine was comparable between b-MDM2KO
mice and WT controls (Fig. 1f). Consistent with the in vivo
observations, our ex vivo analysis in isolated islets showed that
total, ﬁrst and second phases of GSIS were sharply diminished by
b-cell-speciﬁc ablation of MDM2, whereas insulin secretion
induced by potassium chloride (KCl) was similar between
MDM2-deﬁcient islets and WT controls (Fig. 1g,h and
Supplementary Fig. 3). Since WT littermates and RIP-Cre
controls exhibited similar phenotypes in terms of glucose
tolerance and insulin secretion, we therefore only included WT
littermates for comparison in all subsequent experiments.
To test whether pharmacological inhibition of MDM2 impairs
GSIS, we treated C57 mice with nutlin-3a, a small molecule
MDM2 inhibitor that activates p53 by blocking the MDM2–p53
interaction. Treatment with nutlin-3a led to a marked induction
of MDM2 and p53 expression in pancreatic islets, accompanied
with reduction of GSIS (Fig. 2a,b). Furthermore, the mice treated
with nutlin-3a exhibited severe glucose intolerance and defective
GSIS, but normal insulin sensitivity as determined by ITT
(Fig. 2c–e). Similar to the b-MDM2KO mice, treatment with
nutlin-3a signiﬁcantly attenuated glucose- but not L-arginine- or
KCl-induced insulin secretion in mice or isolated islets,
respectively (Fig. 2b,f).
Inactivation of p53 alleviates MDM2-null phenotypes. Since
genetic disruption or pharmacological inhibition of MDM2 led to
p53 activation in pancreatic b-cells, we next explored whether the
inactivation of p53 could reverse glucose intolerance and
defective GSIS in b-MDM2KO mice. To this end, we injected
b-MDM2KO mice with adeno-associated virus (AAV) expressing
FLAG-tagged dominant-negative mutant of p53 (DN-p53)
(in which arginine-172 of p53 was mutated to histidine
(p53R172H)) under the control of a modiﬁed mouse insulin
promoter17,18. Of note, the p53R172H mutant has been shown to
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silence WT p53 activities by blocking the binding ability of p53 to
the DNA responsive elements of its target gene17,18, and the
efﬁciency of our AAV system was previously validated19.
Immunoblotting analysis revealed that the p53 protein level was
increased by approximately threefold relative to its endogenous
levels in islets of mice infected with AAV encoding FLAG-tagged
DN-p53. This was accompanied with a reduction of MDM2
protein level (Fig. 3a). In addition, expression of FLAG-tagged
DN-p53 was conﬁrmed by immunohistochemical staining of
pancreatic tissues using an anti-FLAG antibody (Fig. 3b). AAV-
mediated inactivation of p53 partially reversed glucose
intolerance and defective GSIS in b-MDM2KO mice (Fig. 3c,d).
Of note, AAV-mediated inactivation of p53 had no impact on b-
cell mass, as determined by haematoxylin and eosin staining
(Supplementary Fig. 4). Moreover, inhibition of p53 either by
adenovirus-mediated overexpression of DN-p53 or treatment
with the p53 inhibitor piﬁthrin-a (PFTa) reversed defective GSIS
in MDM2-deﬁcient islets (Fig. 3e–g).
To further conﬁrm whether p53 activation is responsible for
glucose intolerance and defective GSIS in b-MDM2KO mice,
we generated b-cell-speciﬁc MDM2–p53 double KO (DKO) mice
by crossing b-MDM2KO mice with p53ﬂoxed/ﬂoxed mice20.
Augmented expression of p53 by deletion of MDM2 was
abolished in islets of DKO mice (Fig. 4a). Glucose intolerance
and defective GSIS in b-MDM2KO mice were largely reversed
by concomitant genetic deletion of p53, whereas insulin
sensitivity was comparable among the three groups (Fig. 4b–e
and Supplementary Fig. 3).
MDM2 deﬁciency causes mitochondrial dysfunctions in b-cells.
The MDM2–p53 pathway has been implicated in both cell
apoptosis and survival21. We therefore examined the morphology
of pancreatic islets of b-MDM2KO mice and WT controls. The
b-cell mass, pancreatic insulin content and distribution of a- and
b-cells in islets were comparable between b-MDM2KO mice
and WT littermates (Supplementary Fig. 5a–e). There was no
obvious difference in the number of total and docked insulin
granules between b-MDM2KO mice and WT littermates
(Supplementary Fig. 5f–h). The expression levels of key genes
involved in insulin biosynthesis (pancreatic and duodenal
homeobox 1 (PDX1) and insulin 2 (INS2)), glucose uptake
(glucose transporter 2 (GLUT2)), glucose metabolism (glucose
kinase (GCK) and pyruvate dehydrogenase kinase 1 (PDH)) were
also similar between the two groups (Supplementary Fig. 5i).
Electron microscopic analysis showed no obvious difference in
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Figure 1 | Effects of b-cell-speciﬁc deletion ofMDM2 on glucose homeostasis and insulin secretion in mice. (a) Immunoﬂuorescence staining of MDM2
(red) and VAMP2 (as a b-cell marker) (green) in pancreatic sections of 6-week-old male b-cell-speciﬁc MDM2 knockout (b-MDM2KO) mice and its WT
littermates with original magniﬁcation at 400. (b) Pancreatic islets and exocrine (Exo) cells isolated from the above mice were subjected to
immunoblotting using an antibody against MDM2, p53, b-actin or VAMP2 as indicated. The right panel is the densitometric analysis for the relative
abundance of MDM2 and p53 normalized with b-actin. (c–h) Twelve-week-old male b-MDM2KO mice, WT littermates and RIP-Cre controls were used
(n¼6). (c) GTT. (d) Serum insulin levels during the GTT in panel C. (e) ITT. (f) Serum insulin levels on L-arginine stimulation. (g) The isolated islets were
stimulated with glucose (20mM) or KCl (20mM) for 30min, followed by measurement of insulin concentration in the conditional medium (n¼ 5).
(h) Dynamic insulin secretion of the isolated islets in response to glucose stimulation (10mM) using a perfusion system (n¼4). Note that the islets were
maintained in the conditional medium with 2.8mM glucose as basal levels and the insulin content of the isolated islets was comparable between the three
genotypes. All experiments were repeated at least four times and representative images are shown. *Po0.05 (KO versus WT), #Po0.05 (KO versus Cre
control) (Student’s t-test). Scale bar, 50mm. All data are represented as the mean±s.e.m.
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morphology, number and area of mitochondria between
b-MDM2KO mice and WT controls (Supplementary Fig. 5j–l).
On the contrary, glucose-stimulated ATP production and calcium
inﬂux were signiﬁcantly abrogated in MDM2-deﬁcient islets
(Fig. 5a,b) or b-cells treated with nutlin-3a (Supplementary
Fig. 6a,b). Furthermore, increase in ATP/ADP ratio by glucose
stimulation in pancreatic islets was abrogated by MDM2 deletion
(Supplementary Fig. 7)
We next examined the impacts of MDM2 deﬁciency on b-cell
metabolism by measuring oxygen consumption rate (OCR; an
indicator of aerobic metabolism of glucose via TCA cycle
and mitochondrial oxidative phosphorylation), as well as
extracellular acidiﬁcation rate (ECAR; a parameter of glycolytic
ﬂux), with the XF24 extracellular ﬂux analyser. Genetic
deletion or pharmacological inhibition of MDM2 had no
effect on the ECAR level, but signiﬁcantly abolished glucose-
induced OCR (Fig. 5c,d and Supplementary Fig. 6c,d). The
reduced OCR in b-cells with MDM2 inactivation was associated
with a drastic reduction of glucose-stimulated production of
NADH and NADPH, two important intermediates derived
from glucose metabolism in TCA cycle (Fig.5e and
Supplementary Fig. 6e,f). Likewise, adenovirus-mediated
overexpression of p53 resulted in a signiﬁcant reduction of
insulin secretion, ATP and NADPH production and OCR in
response to glucose stimulation (Fig. 6a–e). Noticeably,
short-term overexpression of p53 by B2.4-fold had no obvious
effect on apoptosis and proliferation in MIN6 cells
(Supplementary Fig. 8). On the other hand, reductions in ATP
and NADPH levels and calcium inﬂux in response to glucose
stimulation in MDM2-null islets were reversed by inhibition of
p53 (Figs 4f and 5e–g). Taken together, these data suggest that
disruption of the MDM2–p53 axis impairs TCA cycle in b-cells,
thereby leading to defective GSIS.
Restoration of PC rescues MDM2-null phenotypes in b-cells.
To identify the mechanism whereby MDM2 deﬁciency causes
impaired TCA cycle, we stimulated the islets with the
mitochondrial substrates a-ketoisocaproic acid, which can be
directly metabolized to acetyl-CoA in mitochondria, and
methyl succinate, which directly activates the complex II, supplies
succinate and then converts to oxaloacetate (OAA) in the TCA
cycle (Supplementary Fig. 9a). a-ketoisocaproic acid- but not
methyl succinate-induced insulin secretion and calcium
inﬂux was impaired in MDM2-null islets when compared with its
WT controls (Fig. 7a and Supplementary Fig. 9b,c). Similar result
was also observed in MIN6 b-cells treated with nutlin-3a
(Supplementary Fig. 9d), suggesting that PC-mediated production
of OAA in the TCA cycle could be impaired in b-cells, with
inhibition of MDM2. To test this hypothesis, we ﬁrst measured
OAA level in islets and b-cells on modulation of MDM2 and
p53 levels. Glucose-stimulated OAA production was reduced in
MDM2-deﬁcient islets and MIN6 b-cells treated with nutlin-3a
or with overexpression of p53 when compared with their
corresponding control groups, and was reversed by inactivation
of p53 (Figs 6f and 7b,c). We then measured the expression
of mitochondrial enzymes that can alter OAA production in
TCA cycle. Expression of PC was reduced in isolated islets
but not in hypothalamus of b-MDM2KO mice (Supplementary
Figs 1b and 10a,b), whereas the expression of malic enzyme
1 or 2 in the isolated islets was indistinguishable between
the two groups (Supplementary Fig. 10a). Likewise, the mRNA
level of PC was decreased in MIN6 b-cells treated with
nutlin-3a when compared with vehicle control (Supplementary
Fig. 10c). The reduction in PC expression was reversed by
inhibiting p53 with PFTa in MDM2-deﬁcient islets, suggesting
that MDM2 regulates PC expression via p53 (Supplementary
Fig. 10d).
a
Vehicle Nutlin-3a
p53
MDM2
β-Actin
0.0
0.5
1.0
1.5
2.0 *
MDM2 p53
*
R
el
at
iv
e 
pr
ot
ei
n
e
xp
re
ss
io
n
c
0
0
10
20
30
Nutlin-3a
Vehicle
**
*
Time (min)
G
lu
co
se
  l
ev
el
 (m
mo
l l–
1 )
d
0
0.0
0.2
0.4
0.6
0.8
1.0
*
Time (min)
*
*
In
su
lin
 le
ve
l (n
g m
l–1
)
b
0
5
10
15
Vehicle
Nutlin-3a
Glucose
*
KClBasal
In
su
lin
 le
ve
l
(ng
 m
l–1
 
pe
r i
sle
t p
er
 h
)
fe
0 20 40 60 80
0
25
50
75
100
125
Time (min)
0 2 5 10
0.0
0.2
0.4
0.6
0.8
Time (min)
G
lu
co
se
 le
ve
l
(%
 of
 ba
sa
l)
In
su
lin
 le
ve
l (n
g m
l–1
)Nutlin-3a
Vehicle
Nutlin-3a
Vehicle
Nutlin-3a
Vehicle
Vehicle
Nutlin-3a
95
55
43
KDa
10 20 30 45 60 75 90
10 20 30 60
Figure 2 | Effects of the MDM2 inhibitor nutlin-3a on glucose metabolism and insulin secretion in mice. (a) Islets isolated from 12-week-old male C57
mice were treated with nutlin-3a (10mgml 1) or DMSO as vehicle for 6 h, followed by immunoblotting using an anti-MDM2, -p53 or -b-actin antibody.
Representative immunoblot images from three independent experiments are shown. The lower panel is the densitometric analysis for the relative
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To test whether replenishment of PC could reverse the defects
in MDM2-null islets, islets from b-MDM2KO mice and WT
controls were infected with adenovirus encoding luciferase or PC
(Fig. 7d). PC levels in MDM2-null islets infected with adenovirus
encoding PC was restored to a level similar to its WT controls
(Fig. 7d). Notably, defects in GSIS, glucose-mediated production
of OAA, ATP and NADPH, mitochondrial respiration, as well as
calcium inﬂux in MDM2-null islets were all rectiﬁed by
restoration of PC expression when compared with MDM2-null
islets infected with luciferase control (Fig. 7e–k). These data
support the notion that lowered PC expression is responsible for
the abrogated GSIS on p53 activation.
p53 directly suppresses transcription of PC gene in b-cells.
To test whether p53 directly regulates expression of PC, we
overexpressed WT p53 in MIN6 b-cells by adenoviral gene
transfer system. This analysis demonstrated that p53 suppressed
both protein and mRNA levels of PC (Fig. 8a,b). Through in silico
analysis, we identiﬁed a putative p53 response element (RE)
between  6,810 and  6,781 bp relative to the start codon in the
promoter region of the PC gene (Fig. 8c). To investigate whether
p53 regulates the promoter activity of PC via this potential p53
RE, we cloned the promoter region containing the p53 RE and the
distal promoter (P2, between  92,280 and  91,186 bp) (which
is responsible for glucose-mediated PC expression in pancreatic
b-cells22) of the PC gene into the luciferase reporter vector pGL3
(Fig. 8c). Overexpression of p53 signiﬁcantly inhibited the
promoter activity of PC in b-cells when compared with those
overexpressing green ﬂuorescent protein (GFP) controls (Fig. 8d).
To further conﬁrm that p53 regulates PC promoter activity via
the p53 RE, we generated two mutant constructs in which
the CAT at the ﬁrst central CWWG (where W is A or T) and the
GTC at the second decamer motif were changed to ACG and
AAA through site-speciﬁc mutagenesis, respectively (Fig. 8c,d).
The inhibitory effect of p53 on P2 promoter activity was lost in
the mutants (Fig. 8d). In addition, induction of the PC promoter
activity by glucose was abolished by overexpression of p53
(Fig. 8e). Chromatin immunoprecipitation analysis showed that
there was a signiﬁcant enrichment of p53 to the p53 RE in the PC
promoter (Fig. 8f). In addition, the immunoprecipitated complex
also contained the promoter of MDM2 (Fig. 8f), which contains
the p53 RE23. Collectively, these results indicated that p53
downregulates PC expression by directly interacting with the p53
RE in the PC gene, thereby leading to transcriptional repression.
Inhibition of p53 relieves b-cell dysfunction in diabetes. To test
whether aberrant MDM2–p53–PC signalling axis correlates with
impaired GSIS in islets of db/db diabetic mice, we quantiﬁed
protein expression of MDM2, p53 and PC by immunoblotting.
Protein expression of PC was decreased while p53 and
MDM2 were increased in diabetic islets when compared with
those isolated from WT healthy controls (Fig. 9a). Of note, the
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amount of genomic copy (gc) number per mouse for 2 weeks. The islets were subjected to immunoblotting using an antibody against MDM2, FLAG, p53,
GFP or b-actin as indicated. The right panel is the densitometric analysis for the relative abundance of MDM2 and p53 normalized with b-actin (n¼4).
(b) IHC staining with an anti-FLAG antibody in pancreatic sections of C57 mice injected with AAV-GFP or AAV-DN-p53 (1 1012 gc per mouse) with
original magniﬁcation at 400. Scale bar, 50mm. (c–d) Eight-week-old male b-MDM2KO mice and its WT littermates were injected with AAV-GFP or
AAV-DN-p53 at a dose of 1 1012 gc per mouse for 2 weeks. (c) GTT. (d) Serum insulin levels during GTT in c. (e–g) Isolated islets from b-MDM2KO mice
or its WT littermates were infected with adenovirus encoding luciferase (Adv-Luci) or FLAG-tagged DN-p53 (Adv-DN-p53) (e,f) or treated with PFTa
(10mM) or DMSO as vehicle control (g) for 24 h. (e) The infected islets were subjected to immunoblotting with an anti-p53, -FLAG or -b-actin antibody.
(f,g) Static GSIS in the islets were measured at 30min after glucose stimulation (20mM) (n¼ 5). Note that insulin content in the isolated islets was similar
between different treatment groups. *Po0.05 (KOþAAV-GFP versus WTþAAV-GFP, n¼ 6), #Po0.05 (KOþAAV-GFP versus KOþAAV-DN-p53,
n¼ 6), @Po0.05 (Student’s t-test). All experiments were repeated at least three times and representative immunoblots and IHC images are shown. All
data are represented as the mean±s.e.m.
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increase in MDM2 indicates an upregulation of p53 activity.
Importantly, treatment with the p53 inhibitor PFTa ameliorated
defective GSIS in diabetic islets, and this improvement was linked
to increased PC expression and the partial restoration of ATP and
OAA production in response to glucose stimulation (Fig. 9b–f).
Elevated levels of circulating free fatty acid (FFA) are known to
be associated with type 2 diabetes, and chronic exposure of FFA
impairs GSIS and mitochondrial metabolism in pancreatic islets3.
Similar to the islets isolated from db/db mice, expression of PC was
reduced while MDM2 and p53 were elevated in MIN6 b-cells
treated with palmitic acid when compared with the cells treated
with vehicle control (Fig. 10a). To determine whether the
deteriorative effects of palmitic acid on b-cell functions are
mediated by p53, we generated b-cell-speciﬁc p53 KO mice by
crossing p53ﬂoxed/ﬂoxed mice with RIP-Cre transgenic mice. b-cell-
speciﬁc p53 KO mice displayed a mild increase in b-cell mass when
compared with its WT control, despite that the difference did not
reach statistical signiﬁcance (Supplementary Fig. 11). Palmitic acid
markedly reduced the expression of PC mRNA but induced the
expression of p53 mRNA in WT islets when compared with those
treated with vehicle control (Fig. 10b). In contrast, expression levels
of PC and p53 were indistinguishable between vehicle- and palmitic
acid-treated groups in p53-deﬁcient islets (Fig. 10b). As expected,
palmitic acid strongly inhibited glucose-stimulated intracellular
production of ATP and OAA, as well as insulin secretion, whereas
genetic ablation of p53 in b-cell was able to alleviate these
suppressive effects of palmitic acid on b-cell functions, at least in
part, by restoring mitochondrial metabolism (Fig. 10c–e).
Discussion
Defective insulin secretion exempliﬁed by impaired GSIS is a
hallmark of type 2 diabetes. Mitochondria dysfunction in b-cells
has been postulated as an important culprit for the defective
insulin secretion. However, the underlying mechanisms remain
elusive. In this study, we identiﬁed the MDM2–p53–PC axis as a
key player that couples mitochondrial metabolites to GSIS.
The aberrant activity of this axis is an important contributor to
mitochondrial dysfunction and defective GSIS in b-cells, thereby
leading to type 2 diabetes.
Mitochondria act as a nutrient sensor and metabolite generator
connecting glucose metabolism to insulin secretion in b-cells2. PC
has been proposed as a key player in coupling mitochondrial
metabolism to ﬁrst- and second-phase insulin secretion.
PC-mediated carboxylation of pyruvate not only provides an
anaplerotic input for the TCA cycle and subsequent production
of ATP by supplying OAA but also contributes to the formation
of NADPH, an important amplifying factor for GSIS24,25.
Mass isotopomer multi-ordinate spectral analysis revealed that
PC ﬂux in mitochondria is markedly induced in response to
glucose stimulation in pancreatic b-cells, which is closely
associated with GSIS26. Inhibition of PC abolishes anaplerosis
of the TCA cycle and ATP production, resulting in impaired
GSIS in b-cells, whereas overexpression of PC exerts opposite
effects24,27. PC mediates the protective effects of geniposide and
PPAR-a overexpression against defective GSIS in INS-1E cells
challenged with glucotoxicity and lipotoxicity, respectively28,29.
Such protective effect of PC may be due to its indispensable
role in maintaining the balance of intermediates of glucose
metabolism in the TCA cycle28. Knockdown of PC or inhibition
of PC activity by phenylacetic acid has been shown to potentiate
the detrimental effects of glucotoxicity and lipotoxicity on b-cell
functions30. A genetic linkage study in diabetic patients has
identiﬁed a signiﬁcant association of a single-nucleotide
polymorphism in the PC gene with the magnitude of acute
insulin secretion31. Furthermore, a markedly reduced expression
of PC has been observed in pancreatic islets of both animal
models and patients with type 2 diabetes32,33. However, the
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molecular pathways and pathophysiological relevance of PC
downregulation in diabetic b-cells remain unknown. Our present
study identiﬁed MDM2 and p53 as a Ying–Yang pair to ﬁne tune
the expression of PC in pancreatic b-cells, thereby regulating
TCA cycle, ensuing ATP production and insulin secretion.
Notably, glucose not only acutely induces PC expression but also
promotes MDM2–p53 interaction34,35, suggesting that the
MDM2–p53–PC axis is an integral component mediating GSIS.
Our results also demonstrated that diminished PC expression,
and impaired mitochondrial function and GSIS in the pancreatic
islets of type 2 diabetic mice are attributed to the imbalance
between MDM2 and p53. Furthermore, defective GSIS in
the diabetic islets and MDM2-deﬁcient islets can be reversed by
replenishment with PC, further supporting the role of PC as an
obligatory downstream target of MDM2–p53 in coupling glucose
metabolism, TCA cycle and insulin secretion. In line with our
results, inactivation of p53 by genetic deletion or pharmacological
inhibitor has been shown to improve glucose tolerance by
enhancing mitochondrial respiration, ATP production and GSIS
in mouse models with type 1 and type 2 diabetic, both of which
display defective GSIS at the early stage12.
In both rodents and human, PC expression in different tissues is
controlled by two alternative promoters under different physiolo-
gical circumstances, including the proximal promoter activity in
liver and adipose tissue, and distal promoter activity in pancreatic
b-cells36–38. Several pancreatic islet-speciﬁc transcription factors,
such as PDX1 and forkhead box protein A2, induce PC expression
in a b-cell-speciﬁc manner36–38. Three canonical E-boxes in the
distal promoter act as a glucose RE to mediate the stimulatory
effect of glucose on PC expression in b-cells. The canonical p53 RE
identiﬁed in our present study is located within the promoter of
the PC gene. Furthermore, glucose-stimulated distal promoter
activity of PC is largely abrogated by overexpression of p53
in insulin-secreting cells, whereas mutation of the p53 RE
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abolishes the suppressive effects of p53 on PC expression.
Notably, overexpression of p53 has no obvious effect on distal
promoter activity of PC in HEK293 cells (Supplementary Fig. 12),
indicating that p53 may interact with other b-cell-speciﬁc
transcription co-factor(s) to repress PC expression. On the
other hand, although p53 has been shown to modulate glycolytic
and respiratory pathways via induction of mitochondrial
cytochrome c oxidase in several cancer cell lines5, we did
not observe such effects of p53 or MDM2 in pancreatic
b-cells, suggesting that the metabolic regulation of p53 is highly
cell type-speciﬁc.
Despite the crucial role of p53 in apoptosis and growth arrest21,
we showed that b-cell activation of p53 by genetic or
pharmacological inhibition of MDM2 has no obvious impact
on b-cell mass or death in lean mice (Supplementary Fig. 5a,b).
Apart from MDM2, p53 level is negatively regulated by several
other E3 ubiquitin ligases including MDM4, arf-bp1, Pirh2 and
COP1, via ubiquitination in an MDM2-independent manner39.
Indeed, the differential effects of p53-mediated stress responses
are controlled by distinct E3 ubiquitin ligases39. For example,
b-cell deletion of arf-bp1 leads to overt b-cell loss and diabetes
with ageing, and such phenotypes can be reversed by co-deletion
of p53 (ref. 40). Whether MDM2 and other p53 inhibitors play a
redundant or distinct role in the regulation of b-cell mass or
function is currently unknown. Furthermore, it has been
reported that activation of the apoptotic targets of p53 requires
higher levels of p53, perhaps due to lower p53-binding afﬁnity
in the apoptotic targets41. Consistent with this notion, a marked
elevation of p53 activity by either transgenic overexpression
of its short isoform or its upstream positive regulator (such as
microRNA-200) induces b-cell apoptosis14,42. In contrast, our
study showed that deletion of MDM2 only induces a
modest induction of p53 in b-cells (B2.1-fold), which may be
insufﬁcient to induce the apoptotic gene expression. Therefore, it
is likely that a modest increase of p53 impairs GSIS, whereas a
higher level of p53 induces b-cell apoptosis. On the basis of these
observations, we propose a differential role of p53 at
different stages of type 2 diabetes: p53 expression in pancreatic
islets can be induced by various metabolic insults (such as
lipotoxicity), endoplasmic reticulum and oxidative stresses.
At the early phase of the disease, a modest increase of p53
inhibits GSIS by repressing PC expression in pancreatic b-cells.
However, with the progression of the disease, p53 is further
elevated, which in turn triggers b-cell apoptosis, leading to overt
hyperglycaemia.
p53 in pancreatic b-cells is activated by a number of stress
signals, including lipotoxicity, glucotoxicity, pro-inﬂammatory
cytokines and DNA damage agents11–13,43. In line with
these ﬁndings, we found that expression of p53 is increased in
db/db diabetic islets or in islets challenged with toxic lipids.
Furthermore, several intracellular factors and miRNAs
(such as miRNA200c and transcription factor T-cell factor
7-like 2 (TCF7L2)) has been shown to be a contributor
to elevated p53 expression in b-cells42,44. Nevertheless,
how p53 is activated by different stress signals and whether
this p53 activation is mediated via MDM2 or other
upstream regulators such as TCF7L2 in b-cells need further
investigations.
In summary, our ﬁndings uncovered the MDM2–p53 pathway
as a key molecular connection between mitochondrial
metabolism and insulin secretion by regulating the expression
of PC, which controls the homeostasis of intermediary
metabolites in the TCA cycle (Fig. 10f). Dysfunctional MDM2–
p53–PC axis is an important mediator for defective GSIS in type 2
diabetes, and pharmacological interventions targeting this
signalling axis, such as inhibition of p53 activity, may be effective
for glycaemia control in diabetes. On the other hand, given that
high levels of PC and MDM2 and/or reduction of p53 promote
tumour growth, the MDM2–p53–PC axis may also act as a key
player in linking mitochondrial metabolism with cancer.
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Methods
Materials and cell culture. Rabbit monoclonal antibody against b-tubulin
(Catalogue #2128, 1:2,500 for WB) and mouse monoclonal antibody against p53
(Catalogue #2524, 1:1,000 for WB) were obtained from Cell Signaling Technology.
Rabbit monoclonal antibodies against and PC (Catalogue #Ab128952, 1:1,000 for
WB), and rabbit polyclonal antibody against vesicle-associated membrane protein
2 (VAMP2; Catalogue #ab3347, 1:100 for immunohistochemical (IHC) and 1:2,000
for WB) and p21 (Catalogue #ab7960, 1:1,000 for WB) were purchased from
Abcam. Mouse monoclonal antibody against MDM2 (Catalogue #04-1530, 1:50 for
IHC and 1:500 for WB) was from Merck Millipore. Goat polyclonal antibody
against b-actin (Catalogue #sc-1616, 1:2,000 for WB) was from Santa Cruz
Biotechnology. Mouse monoclonal anti-FLAG antibody (Catalogue #F1804, 1:200
for IHC and 1:5,000 for WB), rabbit polyclonal antibody against glucagon
(Catalogue #SAB4501137, 1:100 for IHC), palmitic acid, fatty acid free-bovine
serum albumin (BSA), L-arginine, nutlin-3a and PFTa were from Sigma. Mouse
monoclonal antibody against insulin (Catalogue #2IP10-D6C4, 1:200 for IHC) was
from HyTest. Collagenase P was obtained from Roche Life Science. Human
recombinant insulin was from Novo Nordisk. Mouse insulinoma MIN6 cells
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(a kind gift from Junichi Miyazaki Laboratory, Osaka University) and HEK293 cells
(American Type Culture Collection) were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS; Life Technologies) and free of mycoplasma
contamination.
Animal studies. All animals were sex- and age-matched, and littermates were
used, as indicated in the ﬁgure legends. Animals were allocated to their
experimental group according to their genotypes, and therefore no randomization
is used, unless otherwise noted. The investigators were not blinded to the
experimental groups. Homozygous MDM2 ﬂoxed mice (MDM2ﬂoxed/ﬂoxed),
obtained from Professor Guillermina Lozano (MD Anderson Cancer Center, The
University of Texas)45, were crossed with RIP-Cre mice (RIP-Creþ -MDM2 / )
to generate heterozygous RIP-Cre-MDM2 ﬂoxed mice (RIP-CreþMDM2ﬂoxed/ )
and MDM2ﬂoxed/ mice. RIP-CreþMDM2ﬂoxed/ mice were intercrossed with
MDM2ﬂoxed/ mice to generate RIP-Cre control mice (RIP-Creþ -MDM2 / ),
WT littermates (MDM2ﬂoxed/ﬂoxed) and b-MDM2KO (RIP-CreþMDM2ﬂoxed/ﬂoxed)
mice. To generate b-cell-speciﬁc MDM2–p53 DKO mice, b-MDM2KO mice
were crossed with p53ﬂoxed/ﬂoxed mice (Jackson Laboratory)20. p53ﬂoxed/ﬂoxed
mice were crossed with RIP-Cre mice to generate b-cell-speciﬁc p53 KO
(RIP-Creþ -p53ﬂoxed/ﬂoxed) mice and its WT littermates (p53ﬂoxed/ﬂoxed). All the
above mice were crossed with C57 BL6/J mice for eight generations and maintained
on the C57 BL6/J genetic background. The mice had free access to food and water
and were kept in cages in a 12-h light/dark cycle and were fed with a standard chow
(Purina) with 20% kcal from protein, 10% kcal from fat and 70% kcal from
combined simple carbohydrates. Glucose tolerance test (GTT) and ITT were
performed in 6-h fast mice46. Brieﬂy, the fasted mice were intraperitoneally
injected with glucose (2 g kg 1) or insulin (0.5 U kg 1) for GTT and ITT,
respectively. Insulin secretion in response to intraperitoneal injection of glucose
(2 g kg 1) or L-arginine (1 g kg 1) was performed in the 6-h-fasted mice46.
Blood samples were taken from the tail vein for the measurement of glucose
and insulin levels using a glucose meter and an insulin ELISA kit (Catalogue
#32380, Antibody and Immunoassay Services, The University of Hong Kong),
respectively.
Twelve-week-old male C57BL6/N mice (purchased from The Laboratory
Animal Unit of The University of Hong Kong) were randomly assigned to
nutlin-3a treatment and dimethylsulphoxide (DMSO) control groups. The mice
were administrated with nutlin-3a (10mg kg 1) or DMSO by oral gavages,
followed by fasting for 6 h. The mice were then subjected to GTT, ITT and insulin
secretory experiments as above. Sixteen-week-old male db/db diabetic mice and its
lean controls were from Jackson Laboratory and maintained on the C57BLKS
genetic background. All animal experimental protocols were approved by the
Animal Ethics Committee of The University of Hong Kong.
Islet isolation and insulin secretion assay. The mice were fasted for 4 h and
killed by cervical dislocation. Pancreatic islets and exocrine cells were isolated as
previously described46. Brieﬂy, pancreas was perfused with collagenase P
(1.4mgml 1) via bile common ducts, followed by digestion at 37 C for 10min.
The digested pancreas was ﬁltered with a 500 and a 70-mm cell strainer. Captured
islets were washed with solution G (HBBS (Gibco) with 0.1% BSA), and then
picked manually under a microscope and cultured in RPMI 1640 with 10% FBS
overnight. The isolated islets with similar size were subjected to assessment for
static and dynamic insulin secretion46. Brieﬂy, isolated islets were washed twice
with Krebs Ringer bicarbonate (KRB) buffer containing 0.1% fatty acid-free BSA
supplemented with 2.8mM glucose for 1 h, followed by treatment with different
stimulants for various time periods as speciﬁed in each ﬁgure legend. For the
perfusion experiment, the isolated islets were incubated with KRB buffer for 30min
and perfused with KRB buffer containing 2.8mM glucose for 6min, and the
perfusate was then switched to KRB buffer containing 10mM glucose. Eluted
fractions were collected at 3-min intervals for 48min. The ﬁrst- and second- phase
insulin secretion was deﬁned as 0–10 and 10–48min, respectively, in islets on
glucose stimulation, according to previous publications46,47. Insulin secreted in
each fraction was measured using the insulin ELISA kit and normalized by the
number of islets.
Measurement of insulin content in pancreas and islets. Pancreas or isolated
islets were incubated with acid-ethanol (1.5% HCl in 70% ethanol) at  20 C
overnight, followed by homogenization. The homogenized lysate was incubated at
 20 C overnight and centrifuged at 10,000g at 4 C. The pancreatic extract was
neutralized with Tris-buffer (pH 7.5), followed by measurement of insulin with the
mouse insulin ELISA.
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Quantitative real-time PCR. Total RNA was extracted from isolated islets or
MIN6 cells using TRIzol reagent (Life Technologies), and cDNA was synthesized
from 0.5 mg total RNA by reverse transcription using an ImProm-II reverse
transcription kit (Promega) with random hexamer primers. Quantitative real-time
PCR was performed using SYBR Green QPCR system (Qiagen) with speciﬁc
primers (Supplementary Table 2). The PCR reactions were performed using
StepOnePlus Real-Time PCR system (Applied Biosystems). The mRNA level
of target gene expression was normalized against the average value of GAPDH
and b-actin.
Generation and puriﬁcation of adenovirus and AAV. To generate adenoviral
vectors for the expression of p53 or PC, cDNA encoding full-length mouse p53 or
human PC was cloned into pshuttle-CMV vector, and then subcloned into
pAdeasy-1 adenoviral backbone vector (Stratagene) via recombination in BJ5183
competent cells48. The positive clones were identiﬁed by digestion with the
restriction enzyme PacI and then conﬁrmed by DNA sequencing. To construct
adenoviral vector encoding DN-p53, PCR-based site-directed mutagenesis was
performed to introduce R172H mutation in mouse p53 using QuikChange II XL
Site-Directed Mutagenesis Kit with the mutagenic primers (Supplementary
Table 2)49. Adenoviruses encoding luciferase were generated in our previous
study48. Adenovirus encoding GFP was obtained from Vector Biolabs. The
adenoviruses were puriﬁed using Vivapure AdenoPACK 100 RT VS-AVPQ102
(Sartorius) according to the manufacturer’s instruction. The titre of adenovirus was
determined by end-point dilution titration in HEK293 cells. Isolated islets with
similar size were selected and cultured overnight for adenovirus infection46. The
islets were infected with the adenovirus at 100 multiplicity of infection (m.o.i.) for
4 h at 37 C (assuming 1,000 cells per islet on average) followed by incubation with
fresh medium for 18 h. MIN6 b-cells were infected with the adenovirus at 50 m.o.i.
and cultured as above.
AAV vector encoding GFP under the control of modiﬁed mouse insulin
promoter was generated as previously described19. To generate AAV vector
encoding DN-p53, cDNA encoding mouse p53R172H was ampliﬁed and cloned
from the pshuttle-DN-p53 vector, and the (BspHI–BglII) PCR fragment was
inserted into the AAV vector with mouse insulin promoter. To generate
recombinant AAV particles, HEK293T cells were co-transfected with the AAV
vector, pRep2Cap8 vector and the helper vector using the helper-free method. On
the third day after transfection, the cells were lysed in a lysis buffer (50mM Tris Cl,
150mM NaCl, 2mM MgCl2, pH 8.0) by freeze and thaw cycle for three times,
followed by polyethylene glycol/aqueous two-phase partitioning50. The titres of
AAV were determined by QPCR analysis using speciﬁc primers targeting AAV
genome (Supplementary Table 2) and the plasmid DNA standard curve.
Eight-week-old male b-MDM2KO mice and its WT littermates were randomly
assigned to intraperitoneal injection with AAV encoding DN-p53 or GFP control
(1 1012 genomic copy number per mouse).
Construction of the luciferase reporter vector and luciferase assay. A reporter
plasmid encoding luciferase under the control of the mouse PC gene promoter was
constructed by amplifying the promoter region spanning  92,280 to  91,186 bp
(the distal promoter 2, the number of nucleotides are relative to the start codon) and
 6,882 to  5,708 bp (promoter region consisting of the putative p53 RE) of PC
using genomic DNA extracted from C57BL/6N mice as template and then subcloned
into pGL3-Basic vector (Promega). The putative p53 RE within the promoter region
were mutated by PCR-based site-directed mutagenesis using the WT vector as the
template. All constructs were conﬁrmed by DNA sequencing. The sequences of all
the primers used for the vector construction are listed in Supplementary Table 2.
MIN6 b-cells were co-transfected with the reporter vector and pRL-TK renilla
luciferase vector (Promega) as transfection efﬁciency control using Lipofectamine
2000 (Life Technologies) for 6 h, followed by infection with adenovirus encoding p53
or GFP at 50 m.o.i. for 24 h. For glucose stimulation experiment, the cells were
incubated with a KRB buffer containing 2.8mM glucose for 1 h, followed by
stimulation with glucose (20mM) for 12 h. The cells were collected for measurement
of luciferase activity using a dual luciferase reporter assay kit (Promega)51.
Chromatin immunoprecipitation. MIN6 cells were infected with adenovirus
encoding FLAG-tagged p53 or luciferase as control at m.o.i.¼ 50 for 24 h,
followed by crosslinking with 1% formaldehyde for 15min at room temperature.
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The crosslinking reaction was stopped by the addition of glycine (ﬁnal
concentration¼ 125mM). The cells were lysed in a lysis buffer (20mM Tris, 2mM
EDTA, 500mM NaCl, 0.1% SDS, 1% NP40, pH 8.0) and were then sonicated to
generate DNA fragments with average size of o1,000 bp. Size of the DNA
fragment was checked by DNA gel electrophoresis. Total cell lysates were subjected
to immunoprecipitation with agarose coupled with anti-FLAG antibody (Catalogue
#A2220, Sigma, 15ml agarose per 1mg total cell lysate) overnight at 4 C. The
complex was washed three times with the lysis buffer and then eluted with elution
buffer (1% SDS and 0.1 M NaHCO3). The crosslinks were reversed by incubating
the complex at 65 C overnight, followed by DNA puriﬁcation using QIAquick
PCR Puriﬁcation Kit (Qiagen). The DNA fragments were analysed by PCR using
speciﬁc PC or MDM2 promoter primers (Supplementary Table 2).
Morphological and immunohistochemical analysis. Pancreases were rapidly
isolated from mice, ﬁxed in 4% paraformaldehyde in 0.1M phosphate buffer, and
were then embedded in parafﬁn and cut into 5-mm-thick sections at 50-mm
intervals. To determine the distribution of MDM2 in pancreas, pancreatic sections
from b-MDM2KO mice and its WT controls were incubated with mouse anti-
MDM2 and rabbit anti-VAMP2 antibodies, followed by staining with secondary
FITC-anti-rabbit IgG- (Catalogue #65-6111, ThermoFisher, 1:500 for IHC) and
Cy5-anti-mouse IgG-conjugated antibodies (Catalogue #A10524, ThermoFisher,
1:500 for IHC), respectively. To detect the expression of FLAG-tagged DN-p53 in
pancreas, pancreatic sections from AAV-injected mice were incubated with
mouse-anti-FLAG antibody, followed by DAB staining. To calculate b-cell mass,
the ratio between the area of islet and the total area of pancreatic section was
multiplied by the weight of pancreas. In all, 4 different parts of the pancreas and 3
tissue slides for each part (total 12 tissue slides per animal) were examined.
For electron microscopic analysis, isolated islets were ﬁxed in 2.5% glutaraldehyde
in cacodylate buffer, osmicated in 1% osmium tetroxide, dehydrated and inﬁltrated,
and polymerized in epoxy resin. Sections (100-nm thickness) were stained with 2%
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aqueous uranyl acetate and Reynold’s Lead Citrate, and examined under a Philips
EM208s transmission electron microscope. Two independent investigators blinded
to sample identity analysed the pancreatic sections.
Measurement of intracellular level of ATP. For measurement of intracellular
ATP, isolated islets or MIN6 cells were incubated in the Krebs buffer with 2.8mM
glucose for 30min, followed by stimulation with glucose (20mM) for 10min.
The level of intracellular ATP was measured using the Luminescence ATP
detection assay system (PerkinElmer) and normalized with protein concentration.
Measurement of calcium inﬂux. Isolated islets or MIN6 cells were loaded with
Fura-2 calcium indicator (ThermoFisher Scientiﬁc) for 30min, followed by
stimulation with glucose (20mM). The ﬂuorescence ratios at 340/380 were
measured using a calcium ion sensing system (IonOptix). The calcium levels
were calculated from three islets of each mouse, and four mice were included in
each group.
Measurement of intracellular levels of metabolites. Levels of NADH, NADPH
and OAA in the islets or MIN6 cells were measured with PicoProbe NADH
Fluorometric Assay Kit (BioVision), PicoProbe NADPH Quantitation
Fluorometric Assay Kit (BioVision) and Oxaloacetate Colorimetric/Fluorometric
Assay Kit (BioVision), respectively, according to the manufacturer’s instructions.
The isolated islets with similar size were used for the above experiments.
Measurement of OCR and ECAR. OCR and ECAR of isolated islets and MIN6
cells were measured in XF24 respirometer platform (Seahorse Bioscience XF24
Extracellular Flux Analyzer). A total of 80–100 islets per well or 1.2 104 MIN6
b-cells were pre-incubated in KRB buffer containing 2.8mM glucose and 1% FBS
for 2 h at 37 C without CO2. Glucose (20mM) was used to stimulate cellular
oxygen consumption, and oligomycin (5mM) was used to inhibit ATP synthesis as
indicated in each ﬁgure.
Caspase 3 and MTT proliferation assays. Activity of caspase 3 was determined
by Caspase-3 Fluorometric assay kit (BioVision, Catalogue #K105-200) according
to the manufacturer’s instructions. Brieﬂy, MIN6 cells infected with adenovirus
encoding luciferase or p53 for 24 h were solubilized in the lysis buffer. A unit of
50mg total protein were incubated with DEVD-AFC substrate at 37 C for 1 h,
followed by measurement of ﬂuorescent intensity (excitation¼ 400 nm;
emission¼ 505 nm). For quantifying cell proliferation, the infected cells were
incubated with 10ml MTT (5mgml 1) at 37 C for an hour. The cells were
solubilized with DMSO, followed by measurement of optical density at 520 nm.
Statistical analysis. Data are presented as mean±s.e.m. All experiments were
repeated at least three times with representative data shown. Animal sample size
for each study was chosen on the basis of literature documentation of similar
well-characterized experiments, and no statistical method was used to
predetermine sample size. Statistical signiﬁcance was determined by unpaired
two-sided Student’s t-test or one-way analysis of variance with Bonferroni
correction for multiple comparisons. A P value of o0.05 represents a signiﬁcant
difference in all statistical comparisons. Data analysis was performed using
GraphPad Prism Software Version 5.0a (GraphPad, San Diego, CA).
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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